Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Tenner

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Cancer|June 8, 2013
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831Alvaro Moreno-Aspitia, David W Hillman, Stephen H Dyar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialEdith A Perez, Monica M Reinholz, David W Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab TrialEdith A Perez, E Aubrey Thompson, Karla V Ballman, et al.
Nature Communications|April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Cancer|June 8, 2013
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831Alvaro Moreno-Aspitia, David W Hillman, Stephen H Dyar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialEdith A Perez, Monica M Reinholz, David W Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2015
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab TrialEdith A Perez, E Aubrey Thompson, Karla V Ballman, et al.
Nature Communications|April 18, 2023
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancerJodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, et al.
Pageof 9